Interleukin-12 regulates the response to chemotherapy in experimental visceral leishmaniasis

Journal of Infectious Diseases

Volumn 182, Issue 5, 2000, Pages 1497-1502

  Murray, Henry W ^a   Montelibano, Christina ^a   Peterson, Ron ^b   Sypek, Joseph P ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; GAMMA INTERFERON ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 4 ANTIBODY; MONOCLONAL ANTIBODY; STIBOGLUCONATE SODIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG RESPONSE; KNOCKOUT MOUSE; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; VISCERAL LEISHMANIASIS;

ANIMAL; ANTIMONY; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-4; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0033783387     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315890     Document Type: Article

References (37)

1. Granulomatous inflammation: Host antimicrobial defense in the tissues in visceral leishmaniasis
2. Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani
3. Interleukin-12 is effective treatment for an established systemic intracellular infection: Experimental visceral leishmaniasis
4. Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis
5. Intracellular antimicrobial activity in the absence of interferon-γ: Effect of interleukin-12 in experimental visceral leishmaniasis in interferon-γ gene-disrupted mice
6. Local suppression of IFN-γ in hepatic granulomas correlates with tissue-specific replication of Leishmania chagasi
7. Clinical spectrum of leishmaniasis
8. Natural history of Leishmania (Leishmania) chagasi infection in northeastern Brazil: Long-term follow-up
9. Differential production of Th1- and Th2-derived cytokines does not determine the generally controlled or vaccine-induced rate of cure in murine visceral leishmaniasis
10. In vivo cytokine profiles in patients with kala-azar: Marked elevation of both interleukin-10 and interferon-γ
11. Interleukin-10 production correlates with pathology in human Leishmania donovani infection
12. Behavior of visceral Leishmania donovani in an experimentally-induced Th2 cell-associated response model
13. IL-12 enhances Th1-type responses in human Leishmania donovani infections
14. Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years
15. Treatment of visceral leishmaniasis (kala-azar): A decade of progress and future approaches
16. Miltefosine: The long-awaited therapy for visceral leishmaniasis?
17. Immunochemotherapy for intracellular Leishmania donovani infection: Interferon-γ plus pentavalent antimony
18. Liposomal amphotericin B in the treatment of visceral leishmaniasis
19. 1984: An in vitro system for determining activity of compounds against the intracellular form of Leishmania donovani
20. The activities of four anticancer alkyllsophospholipids against Leishmania donovani, Trypanosoma cruzi, and Trypanosoma brucei
21. Treatment of experimental visceral leishmaniasis in a T cell-deficient host: Response to amphotericin B and pentamidine
22. Role of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis
23. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms
24. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection: Experimental visceral leishmaniasis
25. Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment
26. IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatitis immunopathology
27. Interleukin 12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity
28. Interleukin-12 in infectious diseases
29. Two roads diverged: Interferon α/β- and interleukin 12-mediated pathways in promoting T cell interferon-γ responses during viral infection
30. Depletion of IL-4 in BALB/c mice with established Leishmania major infection increases the efficacy of antimony and promotes Th1-like responses
31. Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin-12 and Pentostam
32. Interleukin-12 modulates the protective immune response in SCID mice infected with Histoplasma capsulatum
33. Therapy with a combination of low doses of interleukin-12 and chloroquine completely cures blood-stage malaria, prevents severe anemia, and induces immunity to reinfection
34. IL-12 promotes drug-induced clearance of Mycobacterium avium infection in mice
35. Interferon-γ in host antimicrobial defense: Current and future clinical applications
36. Immunochemotherapy for a systemic intracellular infection: Accelerated response using interferon-γ in visceral leishmaniasis in India
37. Response to interferon-γ plus pentavalent antimony in Indian visceral leishmaniasis